BioCryst Pharmaceuticals, Inc. has transferred rights to specific classes of compounds that act as inhibitors of proteins and enzymes in the complement system to 3- Dimensional Pharmaceuticals, Inc. (3DP), a wholly owned subsidiary of Johnson & Johnson. BioCryst will receive an initial payment from 3DP, and will receive royalties on any future sales of complement Read more about Biocryst And 3DP Complement Agreement[…]
Exelixis, Inc. has extended and expanded its oncology research collaboration with Bristol-Myers Squibb Company under which the two companies will continue to identify and validate molecular targets implicated in cancer. The original agreement was established for a three-year term in July 2001. Subject to the terms of their amended agreement, Exelixis and Bristol-Myers Squibb have Read more about Exelixis And Bristol-Myers Squibb Extend Oncology Collaboration[…]
GlaxoSmithKline Plc, Europe’s largest drugmaker, has signed an agreement with France’s Institut Pasteur to develop a SARS vaccine. Scientists from the two organizations aim to produce a sub-unit vaccine, derived from viral proteins. Such a vaccine would protect individuals from the risk of infection, since viral proteins themselves are not infectious. GSK vaccine head Jean Read more about Glaxo And Institut Pasteur Work On Sars Vaccine[…]
NaPro BioTherapeutics, Inc. announced that it has completed the sale of its worldwide generic injectable paclitaxel business to Mayne Pharma for $71.7 million in cash minus an inventory adjustment of $4.6 million to reflect NaPro’s actual inventory as of the date of closing. Leonard P. Shaykin, Chairman and CEO NaPro, stated, “The net proceeds from Read more about Napro Completes Sale Of Worldwide Paclitaxel Business To Mayne Pharma[…]
ILEX Oncology, Inc. and Bioenvision, Inc. announced that development of an oral formulation of clofarabine has been completed. The safety and tolerability of oral clofarabine will be evaluated in adult patients with locally advanced or metastatic solid tumors. ILEX Oncology Inc. has submitted the first part of a New Drug Application (NDA) with the U.S. Read more about Ilex And Bioenvision Announce Completion Of Development Of An Oral Clofarabine Formulation[…]
Spectrum Pharmaceuticals, Inc. and FDC Ltd. announced the signing of a marketing and supply agreement under which FDC will develop and manufacture generic drug products in India, and Spectrum will pursue the regulatory approval, marketing and distribution of the approved drugs for sale in the United States. Nandan Chandavarkar, Executive Director of FDC Ltd., commented, Read more about Spectrum Pharmaceuticals And FDC Enter Into Generic Agreement[…]
SkyePharma PLC announced an agreement with Novartis Pharma AG to jointly develop a new product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The product will combine Novartis’ novel long-acting bronchodilator QAB149 with two SkyePharma technologies SkyeHaler(TM), a breath-activated multi-dose dry powder inhaler (MDDPI) device, to be marketed by Novartis as the Read more about Skyepharma Plans Joint Development With Novartis[…]
IVAX Corporation has entered into agreements with Gedeon Richter Ltd under which a number of generic drugs will be developed for the United States market and distributed exclusively by IVAX’ wholly-owned subsidiary, IVAX Pharmaceuticals, Inc. Dr. Rafick Henein, IVAX Pharmaceuticals, Inc.’s president and chief executive officer, said, “IVAX is very pleased with this new collaboration. Read more about Generic Collaboration For Ivax And Gedeon Richter[…]
ChondroGene Limited has completed the acquisition of GeneNews Inc. The principal asset of GeneNews is proprietary technology, in which ChondroGene presently holds certain licensing rights, in osteoarthritis, rheumatoid arthritis and traumatic joint injury. This technology can be applied to pharmacogenomics and personalized medicine, and in the development of novel diagnostics and therapeutics across a range Read more about Chondrogene Acquires Genenews[…]
Serenex, Inc. announced the signing of a research agreement with Roche which involves the utilization of Serenex’ novel chemoproteomics technologies within Roche’s drug discovery program. The companies will jointly evaluate how Serenex’ technologies may impact the identification of the most appropriate compounds to advance through drug discovery and development Richard S. Kent, M.D., President and Read more about Roche And Serenex Sign Agreement[…]